IBM shares are staging a tentative recovery after suffering their worst single-day loss in 115 years, but the stock remains deeply scarred by a second-quarter earnings miss that exposed a brutal shift in corporate technology spending. The stock edged up 0.89% to €191.20 on Tuesday, bringing its weekly gain to 3.59% — a fragile rebound from the 25.2% crash on July 23 that sent the shares to their lowest point of 2026.
That single session was more punishing than the Black Monday selloff of 1987. Even with the modest bounce, IBM still trades 34.71% below its June 1 high, a chasm that underscores how profoundly the market has repriced the company’s prospects.
The 42% Mainframe Collapse That Shook Wall Street
The trigger was a quarterly report that revealed a 42% plunge in mainframe revenue — far worse than the typical cyclical dip that investors had braced for. The culprit, according to IBM’s own analysis, is a peculiar side effect of the generative AI boom. Corporate clients are rushing to buy physical servers and memory chips ahead of expected price hikes, with chip hardware costs surging nearly 60%. That preemptive buying has cannibalized budgets that would otherwise flow into IBM’s high-margin software and consulting businesses.
CEO Arvind Krishna has pushed back hard against the notion that this is structural decay. He told analysts that one-third of the large enterprise deals that were shelved in the second quarter have already returned, arguing the weakness is “deferred, not destroyed.” The problem, he explained, is timing: Fortune 100 companies prioritized physical AI infrastructure in the near term, leaving software budgets temporarily squeezed.
The market remains unconvinced. Over the past 30 trading days, IBM shares have shed roughly a fifth of their value as institutional investors fled the hybrid-cloud narrative that had underpinned the stock’s earlier rally.
Analysts Split as Price Targets Get Slashed
The recovery has done little to stem the downgrades. Morgan Stanley’s Erik Woodring kept his Equal-Weight rating but slashed his price target by 35.15%, from $293 to $190. HSBC’s Abhishek Shukla went further, downgrading IBM from Hold to Reduce and cutting his target from $231 to $191.
IBM now carries two sell ratings on the Street, though 15 analysts still recommend buying and seven advise holding. The average price target stands at €215.67, implying roughly 12.7% upside from current levels — a modest vote of confidence that masks deep disagreement about whether the company’s portfolio can withstand the AI-driven reordering of enterprise IT budgets.
Should investors sell immediately? Or is it worth buying IBM?
A $10 Billion Quantum Bet and a Blockchain Retreat
While investors digest the near-term pain, IBM is making a pair of strategic moves that signal where management believes the long-term value lies. On Monday, the company confirmed the sale of more than 680 blockchain patent families to Circle, effectively exiting the experimental blockchain push that defined its early-2020s strategy.
The new growth bet is quantum computing. In June, IBM committed $10 billion over five years to its quantum roadmap, targeting “Starling” — what it aims to be the world’s first large-scale fault-tolerant quantum computer, slated for 2029. That is a long-duration wager that offers no near-term relief for the current revenue shortfall, but provides a narrative anchor for investors willing to look past the 2026 turbulence.
Dividends and Cash Flow Hold the Line
Management has not wavered on the financial guardrails that have long defined IBM’s appeal to income investors. The board approved a quarterly dividend of $1.69 per share, payable September 10, 2026, to shareholders of record on August 10 — extending a payout streak that stretches back to 1916 without interruption.
The full-year guidance was trimmed only modestly: IBM now expects constant-currency revenue growth of 4% to 5%, with free cash flow still set to rise by roughly $1 billion. That cash-flow trajectory is the bedrock of the bull case. If the deferred mainframe and software deals materialize once clients finish their initial AI hardware splurge, the current discount could look like a classic overreaction.
Oversold but Not Out of the Woods
Technically, the stock is deeply oversold, and the bounce from the July low suggests value buyers are defending the floor. But IBM remains well below its 50-day and 200-day moving averages, and the annualized volatility has spiked to nearly 85%, leaving the shares acutely sensitive to any fresh news.
The market is now weighing two competing narratives. The optimistic view holds that the second-quarter stumble was a one-off timing mismatch — a hardware price shock that temporarily starved software budgets but will correct itself as clients cycle through their AI infrastructure buildout. The bear case argues that the shift toward specialized AI hardware is permanent, and that IBM’s legacy mainframe and software franchises are being structurally displaced rather than merely delayed.
For now, the stock is caught in the gap between those two stories. The recovery from the historic low suggests the first interpretation has some traction. A full restoration of investor confidence, however, will require proof — in the form of returning deal flow and steady cash generation — that IBM can coexist with the AI infrastructure wave rather than be consumed by it.
Ad
IBM Stock: Buy or Sell?! New IBM Analysis from July 28 delivers the answer:
The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 28.
IBM: Buy or sell? Read more here...
